In a 62-year-old woman with multiple sclerosis, overactive bladder, and mixed urinary incontinence who previously developed urinary retention after an intradetrusor onabotulinumtoxinA (Botox) injection, is it safe to repeat the injection at a lower dose of 50 units?

Re-offering Botox at Lower Dose After Prior Urinary Retention

Yes, you can re-offer intradetrusor onabotulinumtoxinA at 50 units to this patient, but you must have a detailed discussion about the persistent risk of urinary retention and the likely need for clean intermittent catheterization (CIC), as this lower dose still carries retention risk and may provide suboptimal efficacy.

Key Considerations for This Clinical Scenario

The Retention Risk Discussion is Mandatory

Before proceeding, you must counsel this patient extensively about urinary retention risk and potential need for CIC 1. This is a clinical principle that cannot be bypassed, especially given her prior retention episode. The AUA/SUFU guidelines explicitly state that in NLUTD patients who spontaneously void, clinicians must discuss these specific risks before selecting botulinum toxin therapy 1.

Dose Considerations in MS Patients

The standard dosing paradigm presents a challenge here:

• Standard MS dosing: The guidelines recommend 200 units for MS patients with neurogenic lower urinary tract dysfunction, as there is no efficacy difference between 200U and 300U, but there is a dose-dependent relationship with retention risk 1
• Your proposed 50 units: This is substantially below the evidence-based dose for MS patients and falls into the idiopathic OAB range (typically 100U for non-neurogenic patients)

The Evidence on Lower Doses

Recent real-world data shows that 100U doses can be effective even in neurogenic populations 2, though the standard for MS remains 200U. The 50-unit dose you're considering is half of even the idiopathic OAB dose, which raises concerns about:

• Inadequate symptom control in a neurogenic bladder
• Shorter duration of effect (potentially requiring more frequent injections)
• Still carrying retention risk - even 100U causes retention in some patients 3, 4

What the Data Shows About Repeat Injections

The good news: Repeated botulinum toxin injections maintain efficacy and safety over multiple cycles 5, 6. In MS patients specifically, long-term persistence data shows 82.2% of patients are good responders over median 5-year follow-up 6. Treatment efficacy is sustained with repeated injections and minimal adverse events 7.

Clinical Algorithm for This Patient

Step 1: Pre-Treatment Assessment

• Confirm she can perform CIC if needed (manual dexterity, cognitive ability, willingness)
• Assess current bladder emptying pattern and post-void residuals
• Review her MS disability status (EDSS score if available)
• Determine if she's currently on CIC from the prior retention episode

Step 2: Dose Selection Strategy

If she is already performing CIC: Consider 100 units (not 50) as a compromise dose

• This provides better efficacy than 50 units
• Retention risk exists but she's already managing with CIC
• Recent data supports 100U efficacy even in some neurogenic cases 2

If she spontaneously voids and refuses CIC: 50 units is reasonable as harm reduction

• Explicitly document that this is below evidence-based dosing
• Set realistic expectations about likely reduced efficacy
• Plan for closer follow-up at 2-4 weeks post-injection

Step 3: Informed Consent Must Include

• Retention risk persists at any dose - meta-analyses show 20.49% retention rate with onabotulinumtoxinA vs 3.67% placebo 1
• Prior retention history increases her individual risk
• CIC may be temporary or prolonged
• Suboptimal dosing (50U) may result in inadequate symptom control
• Alternative: She could proceed directly to 100U with planned CIC training

Step 4: Post-Injection Monitoring

• Check post-void residual at 1-2 weeks post-injection
• If PVR ≥200 mL, initiate CIC 4
• Reassess symptoms at 4-6 weeks to determine if dose was adequate

Common Pitfalls to Avoid

1. Don't assume lower dose eliminates retention risk - it reduces but doesn't eliminate it
2. Don't use 50 units expecting full MS-level efficacy - this is off-label underdosing
3. Don't proceed without CIC training/capability - this is the safety net
4. Don't forget to document the shared decision-making about dose reduction and retention risk

The Bottom Line

While 50 units is safer than 200 units regarding retention, it's likely inadequate for MS-related neurogenic bladder. A more evidence-based approach would be 100 units with proactive CIC training, accepting that retention may occur but can be managed. The 50-unit option is reasonable only if she absolutely refuses CIC and understands she's accepting both retention risk AND likely treatment failure.